BOSTON — A new intra-nasal imaging tool has been developed to better understand the airways in cystic fibrosis patients. The new imaging tool has been developed using a 1-μm resolution micro-optical coherence tomography (micro- OCT) technology to quantitatively characterize the functional microanatomy of human upper airways.
This is a minimally invasive intranasal imaging approach, using which the authors have conducted a clinical study on age- and sex-matched CF and control groups.
The paper was published in Science Translational Medicine which revealed that the new technique provides high-resolution images of the hair-like structures called cilia that line nasal airways as well as detailed features of the clearance of mucus, which is impaired in people with CF, causing significant morbidity.
Cystic fibrosis is a genetic disease that affects the respiratory and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas.
The imaging catheter, which is about 2-millimeters in diameter, uses optical coherence tomography with a resolution of about 1 micrometer — a 50th the size of a human hair — allowing researchers to probe the nasal passages of patients without even sedating them.
“We’ve done a lot of benchtop imaging with micro-OCT but this is the first time we’ve been able to use it in people,” said co-principal investigator Guillermo Tearney, MD, PhD, a pathologist and investigator for the Department of Pathology and Wellman Center for Photomedicine at Massachusetts General Hospital (MGH), the Remondi Family MGH Research Institute Chair, and professor of pathology at Harvard Medical School (HMS). “It’s unprecedented to see this pathophysiology dynamically in living patients. It will allow us to begin to understand things we never even knew were there.”
Among the researchers’ findings were that in CF patients, the mucus contained more inflammatory cells than in control subjects and it was dehydrated, moving slowly and impacting cilia speed. The researchers were surprised that they were even able to measure the mucus’s reflective quality, which they determined was an indicator of viscosity, and that patches of CF patients’ cilia and epithelium were ablated. “We thought they were there but just not functioning well,” said Tearney, “but in places, they were completely gone.”
The approximately 30,000 cystic fibrosis patients in the United States have an average life expectancy of about 45 years. The new technique will allow clinicians to earlier diagnose diseases that affect the airways, monitor them and optimize drug therapies for individual patients. “Visualizing abnormal mucus will be a powerful tool,” said co-principal investigator Steven M. Rowe, MD, MSPH, director of the Gregory Fleming James Cystic Fibrosis Research Center and a professor of medicine at the University of Alabama at Birmingham. “Now we’ll be able to see how various treatments affect the airway — not only agents intended to fix abnormal mucus, which is applicable to many diseases, but also treatments that repair the basic CF defect itself.”
The researchers expect micro-OCT to have many applications beyond cystic fibrosis — from diagnosing and treating respiratory ailments like primary ciliary dyskinesia, chronic sinus disease, and chronic obstructive pulmonary disease (COPD) to screening the GI tract for diseases and imaging coronary artery cells. “The goal is to figure out who else it can be used to help,” said Rowe, “and make it more broadly accessible as a device.”
For more reference, click on the link